Edition:
United Kingdom

Moleculin announces strategic collaboration to develop immune stimulation drug


Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Moleculin Biotech Inc ::Moleculin announces strategic collaboration to develop immune stimulation drug.Moleculin Biotech - ‍entered into an agreement to collaborate with University of Bergen to expand research on inhibition of brain metastasis by moleculin's pre-clinical drug WP1066​.Moleculin biotech - ‍Moleculin anticipates clinical trial for drug to be ready to begin by end of this year​.Moleculin Biotech - investigational new drug ‍application to study WP1066 ‍in patients with glioblastoma and melanoma has been on hold pending responses to requests from FDA​.Moleculin Biotech - ‍anticipates clinical trial on WP1066 to begin by end of the year. If FDA allows the IND application to proceed based on responses provided​.